Safeguarding Women from Chemical Abortion Act
A bill to provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
This bill, SB4066, aims to withdraw the approval of mifepristone, a drug used for terminating pregnancies, by declaring it ineffective. It also seeks to establish a legal basis for women who suffer harm from chemical abortion drugs to file lawsuits. This bill would affect women who use mifepristone for pregnancy termination and pharmaceutical companies that produce such drugs. If passed, it could lead to significant changes in the availability and legal standing of these drugs.
As of the latest update, SB4066 was introduced on March 11, 2026, and has been referred to the Senate Committee on Health, Education, Labor, and Pensions. This means the bill is currently under review by this committee, which will consider its merits and potential impact.
Key actions in the legislative process so far include the bill being introduced and referred to the appropriate committee. Moving forward, the committee will evaluate the bill, possibly hold hearings, and decide whether to move it forward for further legislative action.
